Interest in protein degradation runs hot as Kymera files for IPO

Atlas-backed Kymera has at least one comparator among preclinical protein degradation companies as it seeks a NASDAQ listing -- and it could soon be followed by another company in the same category.

A regulatory filing Friday said Kymera Therapeutics Inc. hopes to build on more than $204 million in existing equity funding, plus revenue from partnerships with Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) and

Read the full 616 word article

How to gain access

Continue reading with a
two-week free trial.